NatiOnal Referral cenTEr Study of Transthyretin Amyloid Cardiomyopathy(ATTR) Patients on Tafamidis

Inclusion Criteria:

• Diagnosis of ATTRwt amyloidosis.

• 18 years or older;

• evidence of cardiac involvement at echocardiography or cardiac MRI.

• No known prior history of atrial fibrillation or major bradyarrhythmia (seconddegree atrioventricular block, third-degree atrioventricular block, high-gradeatrioventricular block or alternating right and left branch block)

• female patients who are postmenopausal for at least 1 year before the screeningvisit

• patients on therapy or candidates for therapy with tafamidis 61 mg

• voluntary written consent must be given before performance of any study-relatedprocedure not part of standard medical care with the understanding that consent maybe withdrawn by the patient at any time without prejudice to future medical care.

Exclusion Criteria:

• Non-ATTR amyloidosis;

• NYHA class III and IV;

• Pregnant or nursing women;

• Previous pacemaker implantation;

• any serious medical or psychiatric illness that could, in the investigator'sopinion, potentially interfere with a fully comprehension of the written consentform